Related Experiment Video
Updated: May 19, 2026

Phage-Mediated Genetic Manipulation of the Lyme Disease Spirochete Borrelia burgdorferi
Published on: September 28, 2022
A deformylase inhibitor expands therapeutic options for Lyme disease
Kim Lewis1, Pankaj Patil2, Hsin-Wen Liang2
1Northeastern University.
Abstract:
Lyme disease incidence continues to rise globally. This vector-borne infection remains a major public health burden. Broad-spectrum doxycycline and ceftriaxone disrupt the gut microbiome, drive resistance in commensals, and offer suboptimal efficacy against neuroborreliosis. Here we show that forazemin, previously known as BB-83698, is an orally bioavailable peptide deformylase inhibitor with potent and selective bactericidal activity against spirochaetes, including diverse Borrelia species. Targeting the deformylation of nascent peptides, forazemin halted protein synthesis, thereby killing the spirochaetes. In murine models of Lyme borreliosis and neuroborreliosis, short oral dosing regimens cleared infection, and forazemin was more effective than doxycycline in tick-bite prophylaxis. Forazemin preserved microbiome diversity and spared beneficial gut symbionts. These findings support forazemin as a candidate for the treatment and prevention of Lyme disease.
Insights
A new drug, forazemin, shows potent activity against Lyme disease bacteria. It effectively treats Lyme borreliosis and neuroborreliosis in mice while preserving gut microbiome health, offering a promising alternative to current treatments.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Lyme disease incidence is increasing globally, posing a significant public health challenge.
- Current treatments like doxycycline and ceftriaxone have limitations, including gut microbiome disruption, resistance development, and suboptimal efficacy against neuroborreliosis.
Purpose of the Study:
- To evaluate forazemin (BB-83698), a novel peptide deformylase inhibitor, as a potential treatment for Lyme disease.
- To assess forazemin's efficacy and safety in preclinical models of Lyme borreliosis and neuroborreliosis.
Main Methods:
- Forazemin's bactericidal activity against diverse Borrelia species was tested.
- Efficacy was evaluated in murine models of Lyme borreliosis and neuroborreliosis, including tick-bite prophylaxis.
- Impact on gut microbiome diversity and beneficial symbionts was assessed.
Main Results:
- Forazemin demonstrated potent and selective bactericidal activity against Borrelia spirochaetes by inhibiting protein synthesis.
- Oral forazemin cleared infection in murine models of Lyme borreliosis and neuroborreliosis with short dosing regimens.
- Forazemin outperformed doxycycline in tick-bite prophylaxis and preserved gut microbiome diversity.
Conclusions:
- Forazemin is a promising orally bioavailable drug candidate for treating and preventing Lyme disease.
- Its targeted mechanism and favorable microbiome profile offer advantages over existing therapies.
- Further development of forazemin is warranted for Lyme disease management.
Related Concept Videos
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Bacterial DNA Synthesis
Inhibitors of Gram-positive Cell Wall Synthesis
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Anthelminthic Agents
Endocarditis III: Medical Management

